TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study to Evaluate a New Energy Storage and Return Prosthetic Foot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Person is 18 years or older.~2. Currently uses an energy storage and return foot.~3. Person has been a unilateral transfemoral (TF), or transtibial (TT) amputee using a prosthesis for at least 1 year.~4. For TF amputees, the person must be wearing an Ottobock Microprocessor-controlled Knee (MPK) with a compatible prosthetic foot~5. Person weighs ≤ 275 lbs (125 kg) size 26-27cm or ≤ 220 lbs (100 kg) size 24-25cm~6. Person is a K3 ambulator based on Medicare Functional Classification Level (MFCL).~7. Prosthetic foot size is 24 to 27 centimeters.~8. Socket Comfort Score of at least 7~9. Ability to read and understand English~10. A person is able and willing to give consent~Exclusion Criteria:~1. Current prosthetic foot is too old or worn out as assessed by the CPO.~2. TT subject with currently fit with a Proflex XC or TF subject currently fit with a Taleo.~3. Patient is pregnant or planning to become pregnant.~4. Person who has a life-threatening medical condition (i.e. terminal cancer, severe heart disease).~5. Person has conditions that would prevent participation and pose increased risk (e.g. unstable cardiovascular conditions that preclude physical activity such as walking, problems with vestibular system, etc.).~6. Ulceration or skin breakdown of the residual limb.~7. Person currently has residual limb issues that significantly reduce their ability to load the prosthesis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Revo-M to Proflex XC (Type: EXPERIMENTAL): Transtibial amputees randomized to start with Revo-M and cross over to Proflex XC
- Proflex XC to Revo-M (Type: EXPERIMENTAL): Transtibial amputees randomized to start with Proflex XC and cross over to Revo-M
- Revo-M to Taleo (Type: EXPERIMENTAL): Transfemoral amputees randomized to start with Revo-M and cross over to Taleo
- Taleo to Revo-M (Type: EXPERIMENTAL): Transfemoral amputees randomized to start with Taleo and cross over to Revo-M

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 12 months~* Currently treated with Oral Antidiabetic Drugs~* BMI lesser than or equal to 40 kg/m2~* HbA1c greater than or equal 7.5 and lesser than or equal to 11%~Exclusion Criteria:~* Proliferative retinopathy or maculopathy~* Recurrent major hypoglycaemia~* uncontrolled hypertension or any disease or condition (such as renal, hepatic or cardiac) that according to the judgement of the Investigator makes the subject unsuitable for participation in the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nurse-led Case Management for Diabetes and Cardiovascular Disease Patients With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetes and/or heart disease~* Poor disease control (defined as an HbA1c level of at least 8.5%, blood pressure greater than 140/90 mm Hg, LDL cholesterol greater than 130 mg/dL)~* Diagnosis of major depressive disorder~Exclusion Criteria:~* History of psychosis~* At high risk for suicide~* Cognitive impairment~* Current alcohol or substance abuse disorder~* Does not own a telephone~* Currently seeking psychiatric care~* Pregnant or breastfeeding~* Currently enrolled in a Group Health Cooperative disease management program~* Terminal illness~* Plans to leave Group Health Cooperative in less than a year~* Does not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- B (Type: ACTIVE_COMPARATOR): Treatment as usual
- A (Type: EXPERIMENTAL): Case management intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heated Tobacco Products vs Electronic Cigarettes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the study:~1. Able to comply with the study procedures~2. Male or female healthy smokers aged ≥19~3. Smoking at least 10 cigarettes a day~4. Smoking for at least one year~5. Not currently attempting to quit smoking or wishing to do so in the next 30 days (this will be verified at screening by the answer ''NO'' to both questions ''Do you intend to quit in the next 30 days?'' and ''Are you interested in taking part in one of our smoking cessation programs?'')~6. Female smokers not planning to become pregnant are using an acceptable form of contraception.~Exclusion Criteria:~The presence of any of the following will exclude a subject from study enrolment:~1. Use of smokeless tobacco, or any other tobacco products (including e-cigarettes, cigars, chewing tobacco, snus, etc.) within the last 3 months, at baseline and during the whole study.~2. Use of nicotine replacement therapy or other smoking cessation therapies within the last 3 months and at baseline.~3. Self-reported pregnancy, planned pregnancy or breastfeeding.~4. Tobacco industry employees and 1st degree relatives will be excluded in order to safeguard independence of the study~   -

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- IQOS (Type: EXPERIMENTAL): HEAT NOT BURN REDUCED RISK PRODUCT
- E-CIG (Type: ACTIVE_COMPARATOR): ELECTRONIC CIGARETTE REDUCED RISK PRODUCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of COPD.~* Current or previous cigarette smokers with a smoking history of at least 10 pack-years.~* History of at least 1 COPD exacerbation in the 12 months prior to screening.~* Forced expiratory volume in one second (FEV1) of less than or equal to 50% of predicted normal.~Exclusion criteria:~* Diagnosis of asthma.~* Additional respiratory disorders other than COPD (eg, sarcoidosis, alpha-1 antitrypsin deficiency, cystic fibrosis, or active tuberculosis).~* Concurrent use of long-acting beta-agonists, long-acting anticholinergics, inhaled and oral corticosteroids, theophylline, investigational medications, ritonavir, and anti-leukotrienes.~* Lung resection surgery within 1 year of screening.~* Abnormal and clinically significant ECG findings at screening.~* Other inclusion and exclusion criteria will be evaluated at the first study visit.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Feasibility of Florbetapir Quantitation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Readers have undergone Amyvid reader training~* Readers have minimal experience with quantitation of amyloid PET scans~Exclusion Criteria:~* Readers have previously been trained to quantitate amyloid PET scans

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physician Readers (Type: EXPERIMENTAL): Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Lidocaine in the Prevention of Postoperative Vomiting in Elective Tonsil Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 2 and 12 years~* ASA I or II~* Programmed for elective tonsillectomy with or without adenoidectomy under general anesthesia~Exclusion Criteria:~* Obesity, defined as body mass index (BMI) ≥ 95th percentile for age and sex.~* Use of antiemetic drugs during the 24 hours before surgery.~* Gastroesophageal reflux.~* History of allergy to any of the drugs used in the study.~* Down Syndrome.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Group L (Type: ACTIVE_COMPARATOR): Group L Lidocaine load dose 1.5 mg / kg over 5 minutes, followed by continuous infusion of 2 mg / kg / h, which is maintained until the end of surgical procedure
- Group P (Type: PLACEBO_COMPARATOR): Normal saline solution administered under the same regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SGLT2 Inhibition in Combination With Diuretics in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NYHA Functional class II-III HF with prior echocardiographic evidence of LVSD.~* On stable doses of furosemide, or alternative loop diuretic for at least one month.~* Stable Type 2 Diabetes (HbA1c, in the last 3 months, of 6.5% ≤ and ≤10.0%)~* eGFR ≥ 45 ml/min.~* Have stable HF symptoms for at least three months prior to consent~* On stable HF therapy for at least three months prior to consent~* Have not been hospitalised for HF for at least three months prior to consent.~* Women of childbearing potential must agree to take precautions to avoid pregnancy throughout the trial and for 4 weeks after intake of the last dose.~Exclusion Criteria:~* A diagnosis of chronic liver disease and/or liver enzymes that are twice the upper limit of normal~* Systolic BP of \<95mmHg at screening visit.~* Participants on thiazide diuretics.~* Participants receiving renal dialysis~* Participants who have previously had an episode of diabetic ketoacidosis.~* Participants with type 1 diabetes mellitus~* Malignancy (receiving active treatment) or other life threatening disease.~* Pregnant or lactating women~* Participants with difficulty in micturition e.g. severe prostate enlargement~* Allergy to any SGLT2 inhibitor or lactose or galactose intolerance~* Past or current treatment with any SGLT2 inhibitor~* Participants who have participated in any other clinical interventional trial of an investigational medicinal product within 30 days.~* Participants who are unable to give informed consent~* Any other reason considered by the physician to be inappropriate for inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin/Placebo (Type: ACTIVE_COMPARATOR): Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo
- Placebo/Empagliflozin (Type: ACTIVE_COMPARATOR): Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Adult participants with type 2 diabetes mellitus inadequately controlled with non-insulin antihyperglycemic drug(s);~* Signed written informed consent.~Exclusion criteria:~* HbA1c less than (\<) 7.0% (\< 53 millimole per mole \[mmol/mol\]) or greater than (\>) 11% (\> 97 mmol/mol)~* History of type 2 diabetes mellitus for less than 1 year before screening~* Less than 6 months before screening with non-insulin antihyperglycemic treatment~* Change in dose of non-insulin antihyperglycemic treatment in the last 3 month before screening~* Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit and/or initiation of Glucagon-like peptide-1 (GLP-1) receptor agonist in the last 6 months before screening visit~* Participants receiving only non-insulin antihyperglycemic drugs not approved for combination with insulin according to local labeling/local treatment guidelines and/or sulfonylurea or glinide (Note: non-insulin antihyperglycemic drugs not approved for combination with insulin, sulfonylurea and glinide are to be discontinued at baseline)~* Current or previous insulin use except for a maximum of 8 consecutive days (for example, acute illness, surgery) during the last year prior to screening~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (for example, laser, surgical treatment or injectable drugs) during the study period~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HOE901-U300 (Type: EXPERIMENTAL): None
- Lantus (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 19 years or older on screening~* Signed informed consent~* Patients with Essential Hypertension~* Other inclusion applied~Exclusion Criteria:~* Orthostatic hypotension with symptom~* Other exclusion applied

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Irbesartan/Amlodipine (Type: EXPERIMENTAL): None
- Irbesartan (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Very low birth weight infants \< 1500 gr~* Gestational age \< 32 weeks~Exclusion Criteria:~* Genetic anomalies~* Short bowel syndrome~* Not willing to participate~* Allergy to Lactobacillus reuteri components

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Lactobacillus reuteri (Type: EXPERIMENTAL): Lactobacillus reuteri 100 million CFU/day for 3 months
- Nystatin (Type: ACTIVE_COMPARATOR): 50000 unit/3 times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the PMS.~* A male or female infant from the age of 6 weeks at the time of the first vaccination.~* Written informed consent obtained from the parent or guardian of the infant.~Exclusion Criteria:~• At the time of PMS entry, the contraindications and precautions of use indicated in the prescribing information should be checked and the infant must not be included in the PMS if there is any contraindication. Any changes in the locally approved Prescribing Information must be implemented immediately.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 24 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotarix Group (Type: None): Subjects who received 2 oral doses of Rotarix. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Chronic HBV infection, defined as positive serum HBsAg for at least 6 months~* 18 through 75 years of age, inclusive~* HBV DNA ≥ 10\^3 IU/mL~* Receiving treatment with lamivudine with confirmation of HBV reverse transcriptase mutation(s) known to confer resistance to lamivudine (rtM204I/V with or without rtL180M) by central laboratory assessment prior to randomization; adefovir dipivoxil treatment of ≤ 48 weeks at the time of screening (inclusive of combination adefovir dipivoxil + lamivudine at entry) was allowed~* Willing and able to provide written informed consent~* Negative serum pregnancy test (for females of childbearing potential only)~* Calculated creatinine clearance ≥ 50 mL/min~* Hemoglobin ≥ 10 g/dL~* Neutrophils ≥ 1000 /mm\^3~* No prior oral HBV therapy with approved nucleotide and/or nucleoside therapy or other investigational agents for HBV infection other than lamivudine or adefovir dipivoxil~Exclusion Criteria~* Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study~* Males and females of reproductive potential who are not willing to use an effective method of contraception during the study~* Alanine aminotransferase (ALT) ≥ 10 × the upper limit of the normal range (ULN)~* Decompensated liver disease~* Interferon or pegylated interferon therapy within 6 months of the screening visit~* Alpha fetoprotein \> 50 ng/mL~* Evidence of hepatocellular carcinoma~* Coinfection with hepatitis C virus, HIV, or hepatitis D virus~* Significant renal, cardiovascular, pulmonary, or neurological disease~* Received solid organ or bone marrow transplantation~* Receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion~* Proximal tubulopathy~* Known hypersensitivity to the study drugs, the metabolites or formulation excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tenofovir DF (Type: EXPERIMENTAL): TDF plus placebo to match FTC/TDF
- FTC/TDF (Type: EXPERIMENTAL): FTC/TDF plus placebo to match TDF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* This study will be conducted in subjects with histologically confirmed, advanced (stage IV or recurrent disease) RCC who have not received prior systemic therapy for their disease,~Exclusion Criteria:~* Subjects with central nervous system (CNS) metastases~* Prior anticancer therapy for RCC~* Prior investigational therapy/agents within 4 weeks of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete